New York, Jan 29, 2026, 21:08 (EST) — Market closed.
- Shares of Boston Scientific fell roughly 1.6% Thursday, trading on volume that outpaced recent averages.
- The company wrapped up its purchase of chronic-pain tech firm Nalu Medical, marking yet another deal in an active month.
- Attention turns to Friday’s session, with eyes on the company’s Feb. 4 results and outlook.
Shares of Boston Scientific Corp (BSX.N) closed Thursday roughly 1.6% lower at $92.33, having fluctuated between $91.48 and $94.25 during the session.
The decline ended a four-day rally, with about 19 million shares trading hands—well above the 50-day average. The broader market was mixed, and BSX underperformed Abbott, Medtronic, and Stryker for the session.
As trading wraps up, attention turns to Friday and next week. Boston Scientific is set to release its fourth-quarter and full-year 2025 earnings on Feb. 4, followed by a conference call at 8:00 a.m. ET.
Deal activity continues to shape the scene. Boston Scientific announced on LinkedIn that it has “officially completed the acquisition” of Nalu Medical, describing the move as an expansion of its chronic-pain portfolio. LinkedIn
Med-Tech Insights values the upfront cash payment around $533 million and notes that Nalu’s peripheral nerve stimulation system runs wirelessly via an external disc managed by a smartphone app. This technology uses electrical pulses near nerves to dull pain signals.
Raymond W. Cohen, identifying himself as Nalu’s board chairman, called the deal “yet another impactful acquisition.” He also noted collaborating with Boston Scientific M&A chief Charlie Attlan to close the transaction. LinkedIn
Investors are now eyeing how management will factor in this surge of deals. Earlier this month, Boston Scientific announced it would acquire Penumbra for $14.5 billion in a cash-and-stock transaction, marking its biggest move in 20 years.
The looming deal shifts focus squarely onto financing and execution, beyond just sales growth. Traders are keen to catch any new details on timing, balance-sheet strategies, and management’s take on how the additions might impact margins down the line.
The next catalyst could swing either way. Weaker numbers or cautious forecasts might rattle the stock, especially if investors start to worry that the recent acquisition spree is creating more immediate costs than benefits.
The market’s next major checkpoint comes Feb. 4. Attention will zero in on the earnings, guidance, and fresh details on integration — plus whether Boston Scientific can still pursue additional acquisitions.
